Cyclosporin a loaded PLGA nanoparticle: Preparation, optimization, In-Vitro characterization and stability studies

Current Nanoscience

Volumn 6, Issue 4, 2010, Pages 422-431

  Jain, Sanyog ^a   Mittal, Ankit ^a   Jain, Amit K ^a   Mahajan, Rahul R ^a   Singh, Dinesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

AFM; Cyclosporin a; Freeze drying; Nanoparticles; PLGA; XRD

Indexed keywords

AFM; CYCLOSPORIN A; FREEZE DRYING; PLGA; XRD;

DIALYSIS; DIFFRACTION; DRYING; ENCAPSULATION; OPTIMIZATION; PARTICLE SIZE; SURFACE ACTIVE AGENTS; X RAY DIFFRACTION; X RAY DIFFRACTION ANALYSIS;

NANOPARTICLES;

CYCLOSPORIN A; GLUCOSE; MANNITOL; NANOPARTICLE; POLYGLACTIN;

ARTICLE; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; FREEZE DRYING; MOLECULAR WEIGHT; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; ULTRASOUND;

EID: 78449242762     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341310791658937     Document Type: Article

References (35)

1. Page, E.H.; Wexler, D.M.; Guenther, L.C. Cyclosporin A. J. Am. Acad. Dermatol., 1986, 14(5), 785-791.
2. Scholar, E.; Enna, S.J.; David, B.B. Cyclosporin. In xPharm: The Comprehensive Pharmacology Reference; Elsevier: New York, 2007, pp. 1-8.
3. Wu, C.Y.; Benet, L.Z.; Hebert, M.F.; Gupta, S.K.; Rowland, M.; Gomez, D.Y.; Wacher, V.J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther., 1995, 58(5), 492-497.
4. Kahan, B.D. Considerations concerning generic formulations of immunosuppressive drugs. Transpl. Proc., 1999, 31(3), 1635-1641.
5. Olyaei, A.J.; deMattos, A.M.; Bennett, W.M. Switching between cyclosporine formulations. What are the risks? Drug Saf., 1997, 16(6), 366-373.
6. Choi, H.K.; Flynn, G.L.; Amidon, G.L. Percutaneous absorption and dermal delivery of cyclosporin A. J. Pharm. Sci., 1995, 84(5), 581-583.
7. Delie, F.; Blanco-Prieto, M.J. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules, 2005, 10(1), 65-80.
8. Guzman, M.; Molpeceres, J.; Garcia, F.; Aberturas, M.R.; Rodriguez, M. Formation and characterization of cyclosporine-loaded nanoparticles. J. Pharm. Sci., 1993, 82(5), 498-502.
9. Sánchez, A.; Vila-Jato, J.; Alonso, M.J. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. Int. J. Pharm., 1993, 99(2-3), 263-273.
10. Chacón, M.; Berges, L.; Molpeceres, J.; Aberturas, M.R.; Guzman, M. Optimized preparation of poly (lactic-glycolic) microspheres and nanoparticles for oral administration. Int. J. Pharm., 1996, 141(1-2), 81-91.
11. Molpeceres, J.; Chacón, M.; Guzmán, M.; Berges, L.; del Rosario Aberturas, M. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy. Int. J. Pharm., 1999, 187(1), 101-113.
12. Lee, W.-K.; Park, J.-Y.; Yang, E.H.; Suh, H.; Kim, S.H.; Chung, D.S.; Choi, K.; Yang, C.W.; Park, J.-S. Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J. Control. Release, 2002, 84(3), 115-123.
13. Jaiswal, J.; Kumar Gupta, S.; Kreuter, J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J. Control. Release, 2004, 96(1), 169-178.
14. El-Shabouri, M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm., 2002, 249(1-2), 101-108.
15. Hariharan, S.; Bhardwaj, V.; Bala, I.; Sitterberg, J.; Bakowsky, U.; Ravi Kumar, M.N. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm. Res., 2006, 23(1), 184-195.
16. Italia, J.L.; Bhatt, D.K.; Bhardwaj, V.; Tikoo, K.; Kumar, M.N.V.R. PLGA nanoparticles for oral delivery of cyclosporine: Ne.phrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral ®. J. Control. Release, 2007, 119(2), 197-206.
17. Saez, A.; Guzmán, M.; Molpeceres, J.; Aberturas, M.R. Freeze-drying of polycaprolactone and poly(-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur. J. Pharm. Biopharm., 2000, 50(3), 379-387.
18. Abdelwahed, W.; Degobert, G.; Fessi, H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur. J. Pharm. Biopharm., 2006, 63(2), 87-94.
19. Holzer, M.; Vogel, V.; Mantele, W.; Schwartz, D.; Haase, W.; Langer, K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur. J. Pharm. Biopharm., 2009, 72(2), 428-437.
20. Kalaria, D.R.; Sharma, G.; Beniwal, V.; Ravi Kumar, M.N. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in-vivo pharmacokinetics and toxicity studies in rats. Pharm. Res., 2009, 26(3), 492-501.
21. Shaikh, J.; Ankola, D.D.; Beniwal, V.; Singh, D.; Kumar, M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci., 2009, 37(3-4), 223-230.
22. Zhang, L.; Liu, L.; Qian, Y.; Chen, Y. The effects of cryoprotectants on the freeze-drying of ibuprofen-loaded solid lipid microparticles (SLM). Eur. J. Pharm. Biopharm., 2008, 69(2), 750-759.
23. Vandervoort, J.; Ludwig, A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int. J. Pharm., 2002, 238(1-2), 77-92.
24. Scholes, P.D.; Coombes, A.G.A.; Illum, L.; Davis, S.S.; Watts, J.F.; Ustariz, C.; Vert, M.; Davies, M.C. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J. Control. Release, 1999, 59(3), 261-278.
25. [25] Willemer, H. Measurements of temperatures, ice evaporation rates and residual moisture contents in freeze-drying. Dev. Biol. Stand., 1992, 74(123-134.
26. Pikal, M.J. Freeze-drying of proteins. Part I: process design. Biopharm, 1990, 3(8), 18-27.
27. Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev., 2006, 58(15), 1688-1713.
28. Ford, A.W.; Dawson, P.J. The effect of carbohydrate additives in the freezedrying of alkaline phosphatase. J. Pharm. Pharmacol., 1993, 45(2), 86-93.
29. Carpenter, J.F.; Pikal, M.J.; Chang, B.S.; Randolph, T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res., 1997, 14(8), 969-975.
30. Crowe, J.H.; Crowe, L.M.; Carpenter, J.F. Preserving dry biomaterials: the water replacement hypothesis. Biopharm, 1993, 6(3), 28-37.
31. Murakami, H.; Kobayashi, M.; Takeuchi, H.; Kawashima, Y. Preparation of poly(-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm., 1999, 187(2), 143-152.
32. De Jaeghere, F.; Allemann, E.; Leroux, J.C.; Stevels, W.; Feijen, J.; Doelker, E.; Gurny, R. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm. Res., 1999, 16(6), 859-866.
33. Quintanar-Guerrero, D.; Ganem-Quintanar, A.; Allemann, E.; Fessi, H.; Doelker, E. Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J. Microencapsul., 1998, 15(1), 107-119.
34. Miller, S.C.; Drabik, B.R. Rheological properties of poloxamer vehicles. Int. J. Pharm., 1984, 18(3), 269-276.
35. Cavatur, R.K.; Vemuri, N.M.; Pyne, A.; Chrzan, Z.; Toledo-Velasquez, D.; Suryanarayanan, R. Crystallization behavior of mannitol in frozen aqueous solutions. Pharm. Res., 2002, 19(6), 894-900.